Dr. Conny Bogentoft Will be Presenting 'Technology Transfer at the Karolinska Institutet' at Bio2008 in San Diego on Tuesday 17th June
This talk will cover the key points that have enabled KD to build aportfolio in less than 5 years that, has three companies with products on themarket; four with compounds at phase II and five with compounds at phase I.
The unique evergreen structure and exclusive deal flow from KarolinskaInstitutet Innovations AB enable innovations to be taken from seed stagethrough to optimal exit. Ensuring access to appropriate milestone drivencapital funding and key competencies required in each development phaseenables companies to mature rapidly.
Providing far more than seed capital Karolinska Development also providescompanies with the skills and expertise needed in order to build valueefficiently. The Karolinska Development management has long industrialexperience within development and business, contributing senior R&D expertisethat accelerates product and business development. This management team issupplemented a network of experts that includes more than 300 specialists,including; project managers, business development experts, general managementand board members from a range of companies.
About Karolinska Development AB
Karolinska Development commercializes Nordic life science innovation.Early stage investment enables value building through long term lead investorposition, from seed stage to the market.
About Karolinska Institutet
Karolinska Institutet is one of the leading medical universities inEurope. Through research, education and information, Karolinska Institutetcontributes to improving human health. Each year, the Nobel Assembly atKarolinska Institutet awards the Nobel Prize in Physiology or Medicine. Formore information, visit http://www.ki.se
SOURCE Karolinska Development AB (PUBL)
You May Also Like